Neurofibroma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 23: Line 23:
|+Differentiating neurofibroma from other diseases
|+Differentiating neurofibroma from other diseases
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease entity
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease entity
!Etiology (Genetic or others)
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological findings
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological findings
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Immunohistochemical staining
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Immunohistochemical staining
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Common site of involvement
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Common site of involvement
!Clinical manifestations
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other associated features
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other associated features
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Neurofibroma'''
| style="background:#DCDCDC;" align="center" + |'''Neurofibroma'''
|
|
|
* Uniphasic, low to moderate cellularity
* Uniphasic, low to moderate cellularity
Line 64: Line 67:
|
|
* Can occur anywhere
* Can occur anywhere
|
|
|
* Nerve often not identified, incorporates nerve, axons often present in lesion
* Nerve often not identified, incorporates nerve, axons often present in lesion
Line 75: Line 79:
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Schwannoma'''
| style="background:#DCDCDC;" align="center" + |'''Schwannoma'''
|
|
|
* Encapsulated
* Encapsulated
Line 91: Line 96:
|
|
* NF-2 associated
* NF-2 associated
|
|
|
|
|
Line 98: Line 104:
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Palisaded encapsulated neuroma'''
| style="background:#DCDCDC;" align="center" + |'''Palisaded encapsulated neuroma'''
|
|
|
* Solitary
* Solitary
Line 110: Line 117:
|
|
* 90% lesions affect the face
* 90% lesions affect the face
|
|
|
* No known familial association
* No known familial association
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Traumatic neuroma'''
| style="background:#DCDCDC;" align="center" + |'''Traumatic neuroma'''
|
|
|
* Numerous well formed small nerve twigs
* Numerous well formed small nerve twigs
Line 121: Line 130:
|
|
* History of trauma or surgery
* History of trauma or surgery
|
|
|
|
|
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Neurotized Melanocytic Nevus'''
| style="background:#DCDCDC;" align="center" + |'''Neurotized Melanocytic Nevus'''
|
|
|
* Superficial classic nevoid [[melanocytes]]
* Superficial classic nevoid [[melanocytes]]
Line 135: Line 146:
Negative for:
Negative for:
* Factor XIIIa
* Factor XIIIa
|
|
|
|
|
Line 140: Line 152:
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Cutaneous Myxoma (Superficial angiomyxoma)'''
| style="background:#DCDCDC;" align="center" + |'''Cutaneous Myxoma (Superficial angiomyxoma)'''
|
|
|
* [[Spindle]] to stellate cells with oval nuclei
* [[Spindle]] to stellate cells with oval nuclei
Line 148: Line 161:
|
|
* Associated with Carney complex
* Associated with Carney complex
|
|
|
|
|
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Nerve sheath myxoma'''
| style="background:#DCDCDC;" align="center" + |'''Nerve sheath myxoma'''
|
|
|
* Markedly hypocellular with abundant [[mucopolysaccharides]]
* Markedly hypocellular with abundant [[mucopolysaccharides]]
Line 157: Line 172:
|Positive for:
|Positive for:
* [[S100|S-100]]
* [[S100|S-100]]
|
|
|
|
|
Line 162: Line 178:
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Malignant peripheral nerve sheath tumor'''
| style="background:#DCDCDC;" align="center" + |'''Malignant peripheral nerve sheath tumor'''
|
|
|
* Generalized atypia
* Generalized atypia
Line 168: Line 185:
|Positive for:
|Positive for:
* [[S100|S-100]] (30%)
* [[S100|S-100]] (30%)
|
|
|
|
|
Line 173: Line 191:
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Dermatofibrosarcoma protuberans (DFSP)'''
| style="background:#DCDCDC;" align="center" + |'''Dermatofibrosarcoma protuberans (DFSP)'''
|
|
|
* More cellular
* More cellular
Line 184: Line 203:
|
|
* Deep soft tissue of posterior neck
* Deep soft tissue of posterior neck
|
|
|
|-
|-
| style="background:#DCDCDC;" align="center" + |'''Spindle cell lipoma'''
| style="background:#DCDCDC;" align="center" + |'''Spindle cell lipoma'''
|
|
|
* Delicate encapsulation
* Delicate encapsulation
Line 195: Line 216:
* CD34 (strongly)
* CD34 (strongly)
* [[S-100]](stains only fat cells)
* [[S-100]](stains only fat cells)
|
|
|
|
|
|
|
|-
|-
|style="background:#DCDCDC;" align="center" + |'''Ganglioneuroma'''
| style="background:#DCDCDC;" align="center" + |'''Ganglioneuroma'''
|
|
|
|
|
|
Line 206: Line 230:
|
|
|-
|-
|style="background:#DCDCDC;" align="center" + |'''Myxoid liposarcoma'''
| style="background:#DCDCDC;" align="center" + |'''Myxoid liposarcoma'''
|
|
|
|
|
|
Line 213: Line 239:
|
|
|-
|-
|style="background:#DCDCDC;" align="center" + |'''Leiomyoma'''
| style="background:#DCDCDC;" align="center" + |'''Leiomyoma'''
|
|
|
|
|
|
Line 220: Line 248:
|
|
|-
|-
|style="background:#DCDCDC;" align="center" + |'''Inflammatory myofibroblastic tumor'''
| style="background:#DCDCDC;" align="center" + |'''Inflammatory myofibroblastic tumor'''
|
|
|
|
|
|
Line 227: Line 257:
|
|
|-
|-
|style="background:#DCDCDC;" align="center" + |'''Acrochorda'''
| style="background:#DCDCDC;" align="center" + |'''Acrochorda'''
|
|
|
|
|
|

Revision as of 15:51, 22 April 2019

Neurofibroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neurofibroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neurofibroma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurofibroma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurofibroma differential diagnosis

CDC on Neurofibroma differential diagnosis

Neurofibroma differential diagnosis in the news

Blogs on Neurofibroma differential diagnosis

Directions to Hospitals Treating Neurofibroma

Risk calculators and risk factors for Neurofibroma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]

Overview

Neurofibroma must be differentiated from schwannoma, dermatofibrosarcoma protuberans (DFSP), ganglioneuroma, and melanocytic nevus.

Differential Diagnosis

Neurofibroma must be differentiated from:[1][2][3]

Differentiating neurofibroma from other diseases
Disease entity Etiology (Genetic or others) Histopathological findings Immunohistochemical staining Risk factors Common site of involvement Clinical manifestations Other associated features
Neurofibroma
  • Uniphasic, low to moderate cellularity
  • Non-encapsulated
  • Random pattern, only rare palisading
  • No well formed verocy bodies
  • Cells separated by collagen bundles
  • Hypocellular with abundant mucinous matrix
  • No peripheral perineural capsule
  • Frequent mast cells
  • Contains neural fibroblasts and fibrillary collagen
  • Random proliferation of Schwann cells and scattered admixed axons
  • No nevoid cells
  • No epithelial component
  • Diffuse growth pattern
  • Scant cytoplasm
  • Wavy cells with buckled nuclei
  • Pseudomeissnerian bodies representing specific differentiation may be present
  • Lacks storiform pattern

Neurofibroma with degenerative atypia ("ancient change") has following microscopic features:

  • Localized cells with large pleomorphic nuclei, cytoplasmic nuclear inclusions, smudgy chromatin, and inconspicuous nuclei
  • Absent or very low mitotic activity
  • Low to moderate cellularity
Positive for:
  • NF-1 associated
  • Can occur anywhere
  • Nerve often not identified, incorporates nerve, axons often present in lesion
  • Seldom cystic
  • Frequently multiple
  • Widespread soft tissue infiltration
  • Tends to displace adnexa
  • <2cm in diameter
  • Lacks distinct lobulation
  • Lacks fat
Schwannoma
  • Encapsulated
  • Biphasic (majority entirely hypercellular Antoni A & hypocellular Antoni B)
  • Palisading
  • Verocay bodies
  • Infrequent extracellular collagen
Positive for:
  • NF-2 associated
  • Nerve often identifiable
  • Eccentric to nerve, axons generally absent within lesion
  • Occasionally cystic
Palisaded encapsulated neuroma Positive for:
  • EMA

Negative for:

  • 90% lesions affect the face
  • No known familial association
Traumatic neuroma
  • Numerous well formed small nerve twigs
  • Limited soft tissue infiltration
  • Contains axons in haphazardly arranged nerves
  • History of trauma or surgery
Neurotized Melanocytic Nevus
  • Superficial classic nevoid melanocytes
  • Congenital and nested growth patterns
  • More abundant cytoplasm
  • Tends to surround adnexa
Positive for:

Negative for:

  • Factor XIIIa
Cutaneous Myxoma (Superficial angiomyxoma)
  • Spindle to stellate cells with oval nuclei
  • 1-5cm in diameter
Positive for:
  • Associated with Carney complex
Nerve sheath myxoma Positive for:
Malignant peripheral nerve sheath tumor
  • Generalized atypia
  • Increased mitotic activity
  • Diffuse hypercellularity
Positive for:
Dermatofibrosarcoma protuberans (DFSP)
  • More cellular
  • Distinct storiform pattern
  • Usually forms a mass
Strongly positive for:

Negative for:

  • Deep soft tissue of posterior neck
Spindle cell lipoma
  • Delicate encapsulation
  • Mostly cases contain fat
  • Floret cell formation
  • No degenerative atypia
Positive for:
  • CD34 (strongly)
  • S-100(stains only fat cells)
Ganglioneuroma
Myxoid liposarcoma
Leiomyoma
Inflammatory myofibroblastic tumor
Acrochorda

References


Template:WikiDoc Sources